MENLO PARK, Calif. — AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in November.
Stifel 2023 Healthcare Conference
- Eric Easom, Co-Founder, President and CEO will provide a corporate overview on Wednesday, November 15 at 3:00 p.m. ET.
6th Annual Evercore ISI HealthCONx Conference
- Eric Easom, Co-Founder, President and CEO will provide a corporate overview on Wednesday, November 29 at 8:45 a.m. ET.
A webcast of the presentations can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our initial candidate is epetraborole, which we are studying as a once-daily, oral treatment with a novel mechanism of action for patients with nontuberculous mycobacteria (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, that leads to irreversible lung damage and can be fatal.
COMPANY CONTACT:
Lucy O. Day
Chief Financial Officer
[email protected]
INVESTOR AND MEDIA CONTACT:
Anne Bowdidge
[email protected]